Radius Health, Inc. (RDUS)
USD 29.06
(-0.03%)
USD 29.06
(-0.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 804.29 Million USD | -7.35% |
| 2022 | 868.12 Million USD | 32.62% |
| 2021 | 654.58 Million USD | 19.13% |
| 2020 | 549.49 Million USD | 110.19% |
| 2019 | 261.43 Million USD | 15.51% |
| 2018 | 226.33 Million USD | 3.05% |
| 2017 | 219.62 Million USD | 563.43% |
| 2016 | 33.1 Million USD | 56.3% |
| 2015 | 21.18 Million USD | -52.88% |
| 2014 | 44.95 Million USD | -84.5% |
| 2013 | 290.05 Million USD | 28.37% |
| 2012 | 225.96 Million USD | 23.31% |
| 2011 | 183.24 Million USD | 217463.25% |
| 2010 | 84.22 Thousand USD | 124.94% |
| 2009 | 37.44 Thousand USD | -98.79% |
| 2008 | 3.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 926.83 Million USD | 8.7% |
| 2023 Q1 | 852.65 Million USD | -4.64% |
| 2023 Q4 | 808.37 Million USD | 0.51% |
| 2023 Q3 | 804.29 Million USD | -13.22% |
| 2023 FY | 804.29 Million USD | -7.35% |
| 2022 Q1 | 420.09 Million USD | -3.17% |
| 2022 Q3 | 868.12 Million USD | 102.91% |
| 2022 Q4 | 894.11 Million USD | 2.99% |
| 2022 FY | 868.12 Million USD | 32.62% |
| 2022 Q2 | 427.84 Million USD | 1.84% |
| 2021 Q2 | 419.94 Million USD | -0.28% |
| 2021 Q4 | 433.84 Million USD | 1.19% |
| 2021 Q3 | 428.73 Million USD | 2.09% |
| 2021 Q1 | 421.11 Million USD | 33.59% |
| 2021 FY | 654.58 Million USD | 19.13% |
| 2020 FY | 549.49 Million USD | 110.19% |
| 2020 Q2 | 284.51 Million USD | 3.19% |
| 2020 Q3 | 304.53 Million USD | 7.04% |
| 2020 Q4 | 315.24 Million USD | 3.52% |
| 2020 Q1 | 275.73 Million USD | 5.47% |
| 2019 Q3 | 251.74 Million USD | 2.99% |
| 2019 Q2 | 244.43 Million USD | 3.19% |
| 2019 Q4 | 261.43 Million USD | 3.85% |
| 2019 Q1 | 236.86 Million USD | 4.65% |
| 2019 FY | 261.43 Million USD | 15.51% |
| 2018 Q3 | 224.35 Million USD | 1.73% |
| 2018 FY | 226.33 Million USD | 3.05% |
| 2018 Q1 | 208.82 Million USD | -4.92% |
| 2018 Q2 | 220.52 Million USD | 5.6% |
| 2018 Q4 | 226.33 Million USD | 0.88% |
| 2017 Q2 | 32.1 Million USD | -3.48% |
| 2017 Q1 | 33.26 Million USD | 0.48% |
| 2017 FY | 219.62 Million USD | 563.43% |
| 2017 Q4 | 219.62 Million USD | 9.21% |
| 2017 Q3 | 201.09 Million USD | 526.37% |
| 2016 FY | 33.1 Million USD | 56.3% |
| 2016 Q1 | 18.91 Million USD | -10.69% |
| 2016 Q4 | 33.1 Million USD | 28.76% |
| 2016 Q3 | 25.7 Million USD | 31.36% |
| 2016 Q2 | 19.57 Million USD | 3.47% |
| 2015 Q4 | 21.18 Million USD | 18.05% |
| 2015 Q3 | 17.94 Million USD | -55.35% |
| 2015 FY | 21.18 Million USD | -52.88% |
| 2015 Q1 | 39.74 Million USD | -11.59% |
| 2015 Q2 | 40.18 Million USD | 1.1% |
| 2014 Q3 | 47.54 Million USD | 14.89% |
| 2014 Q2 | 41.38 Million USD | 21.28% |
| 2014 Q1 | 34.12 Million USD | -88.24% |
| 2014 FY | 44.95 Million USD | -84.5% |
| 2014 Q4 | 44.95 Million USD | -5.45% |
| 2013 Q1 | 227.01 Million USD | 0.47% |
| 2013 Q3 | 290.37 Million USD | 4.04% |
| 2013 Q4 | 290.05 Million USD | -0.11% |
| 2013 FY | 290.05 Million USD | 28.37% |
| 2013 Q2 | 279.09 Million USD | 22.94% |
| 2012 Q2 | 208.08 Million USD | 10.86% |
| 2012 Q3 | 216.33 Million USD | 3.96% |
| 2012 Q4 | 225.96 Million USD | 4.45% |
| 2012 FY | 225.96 Million USD | 23.31% |
| 2012 Q1 | 187.7 Million USD | 2.43% |
| 2011 Q4 | 183.24 Million USD | 41.0% |
| 2011 Q3 | 129.96 Million USD | 5.28% |
| 2011 Q2 | 123.44 Million USD | 130705.34% |
| 2011 Q1 | 94.37 Thousand USD | 12.04% |
| 2011 FY | 183.24 Million USD | 217463.25% |
| 2010 Q2 | 52.91 Thousand USD | 7.91% |
| 2010 FY | 84.22 Thousand USD | 124.94% |
| 2010 Q4 | 84.22 Thousand USD | 38.48% |
| 2010 Q3 | 60.82 Thousand USD | 14.96% |
| 2010 Q1 | 49.03 Thousand USD | 30.94% |
| 2009 Q3 | 34.3 Thousand USD | 31.4% |
| 2009 Q2 | 26.1 Thousand USD | 24.41% |
| 2009 Q1 | 20.98 Thousand USD | -99.32% |
| 2009 FY | 37.44 Thousand USD | -98.79% |
| 2009 Q4 | 37.44 Thousand USD | 9.15% |
| 2008 Q4 | 3.1 Million USD | -32.61% |
| 2008 Q2 | 12.99 Million USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 3.1 Million USD | 0.0% |
| 2008 Q3 | 4.6 Million USD | -64.6% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 15.148% |
| Embecta Corp. | 2.03 Billion USD | 60.499% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -70.519% |
| Dynavax Technologies Corporation | 375.02 Million USD | -114.464% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -21.716% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -14.204% |
| PainReform Ltd. | 2.69 Million USD | -29788.146% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -390.705% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -13000.039% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1350.478% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -8645.504% |
| Cosmos Health Inc. | 30.25 Million USD | -2558.588% |
| Journey Medical Corporation | 56.49 Million USD | -1323.547% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -13000.039% |
| Safety Shot Inc | 3.89 Million USD | -20564.977% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1986.301% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -487.626% |
| Bright Green Corporation | 6.43 Million USD | -12392.657% |
| Procaps Group, S.A. | 462.06 Million USD | -74.064% |
| Theratechnologies Inc. | 98.63 Million USD | -715.387% |
| Harrow Health, Inc. | 241.75 Million USD | -232.691% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -9085.587% |
| Biofrontera Inc. | 23.13 Million USD | -3375.906% |
| DURECT Corporation | 30.4 Million USD | -2545.169% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -64.996% |
| Cronos Group Inc. | 43.73 Million USD | -1738.962% |
| OptiNose, Inc. | 194.33 Million USD | -313.868% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 1.6% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1560.213% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3733.946% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -343.472% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -21221.883% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1431.508% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -5747.54% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1790.49% |
| Phibro Animal Health Corporation | 725.54 Million USD | -10.854% |
| Procaps Group S.A. | 462.06 Million USD | -74.064% |
| Alvotech | 1.88 Billion USD | 57.277% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -5635.915% |
| Viatris Inc. | 27.21 Billion USD | 97.045% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2504.397% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -789.908% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1287.25% |
| Tilray Brands, Inc. | 892.11 Million USD | 9.845% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -265.919% |
| Shineco, Inc. | 47.6 Million USD | -1589.625% |
| PetIQ, Inc. | 645.22 Million USD | -24.652% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -366299.103% |
| Incannex Healthcare Limited | 5.83 Million USD | -13695.712% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 21.102% |
| Alimera Sciences, Inc. | 107.35 Million USD | -649.194% |
| Silver Spike Investment Corp. | 3 Million USD | -26622.098% |
| Assertio Holdings, Inc. | 148.41 Million USD | -441.916% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -42321.142% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3673.215% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -11347.338% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9372.788% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -363.87% |
| Hempacco Co., Inc. | 18.82 Million USD | -4173.046% |
| Talphera, Inc. | 6.29 Million USD | -12686.804% |
| Alvotech | 1.88 Billion USD | 57.277% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -365.985% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 3.707% |
| Currenc Group, Inc. | 177.67 Million USD | -352.673% |
| Kamada Ltd. | 109.96 Million USD | -631.384% |
| Indivior PLC | 1.95 Billion USD | 58.781% |
| Evoke Pharma, Inc. | 9.64 Million USD | -8236.267% |
| Flora Growth Corp. | 17.22 Million USD | -4570.131% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9372.788% |
| Evolus, Inc. | 209.68 Million USD | -283.567% |
| HUTCHMED (China) Limited | 536.38 Million USD | -49.946% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 7.922% |
| Akanda Corp. | 12.66 Million USD | -6248.546% |